The original PD-L1 cut-off point for durvalumab, an anti-PD-L1 antibody, was determined using ORR data from 50 patients with R/M HNSCC enrolled in the phase I/II study (Study 1108; refs. 4, 14). Here, CD274 is linked to head and neck squamous cell carcinoma.